Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Community Cohort Study of Songling Xuemaikang plus calcium antagonist in hypertension
ChiCTR2200065775Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Nov 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of songling xuemaikang in hypertension (HTN) (2 arms), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoints: Blood pressure, Traditional Chinese Medicine (TCM) syndrome assessment and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
songling xuemaikang
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR2200065775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065775.